EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of a monoclonal antibody based enzyme immunoassay abbott pap eia kit for prostatic acid phosphatase


Nishinihon Journal of Urology 46(4): 801-807
Evaluation of a monoclonal antibody based enzyme immunoassay abbott pap eia kit for prostatic acid phosphatase
The clinical application of enzyme immunoassay (EIA) for prostatic acid phosphatase (PAP) is reported. PAP concentration was measured by ABBOTT PAP-EIA kit. Serum samples were collected from 56 healthy individuals (30 males, 26 females), and 35 patients with benign prostatic hypertrophy, 10 patients with chronic prostatitis, 20 patients with chronic renal failure, 16 patients (83 samples) with prostatic cancer, and 18 patients with various other malignancies (renal cell carcinoma (2), renal pelvic tumor (1), ureter tumor (1), bladder tumor (4), testicular cancer (3), lung cancer (2) cases and gastrointestinal cancer 5 cases.) Intraassay coefficients of variation (% CV) arranged from 0.39-8.82; interassay % CV ranged from 6.63 to 12.4. The recovery rates in the recovery test were 100.8 .+-. 10.5%. PAP concentrations in normal males (n = 30) were 0.924 .+-. 0.35 ng/ml, and normal females (n = 22) were 0.821 .+-. 0.44 ng/ml. Upper limit of normal-ranged PAP concentration was 1.624 ng/ml (mean + 2 SD). Significant correlation (r = 0.95. P < 0.01) was seen between RIA [radioimmunoassay] and EIA method. PAP levels in benign prostatic hypertrophy (n = 35) were 0.787 .+-. 0.32 ng/ml. False positive results were not observed. Elevations in PAP concentrations above 1.624 ng/ml were observed in 25% of patients with stage A prostatic cancer, 25% with stage B, 100% with stage C and 100% with stage D prior to treatment. PAP levels measured by ABBOTT PAP-EIA kit were as useful for the diagnosis of prostatic cancer as RIA method.


Accession: 005395283



Related references

Evaluation of a monoclonal antibody-based enzyme immunoassay (IQ(Bio) PAP-AELIA kit) for prostatic acid phosphatase. Hinyokika Kiyo. Acta Urologica Japonica 33(10): 1703-1707, 1987

Monoclonal antibody-based radioimmunoassay compared with conventional enzyme immunoassay in the detection of prostatic acid phosphatase. European Urology 10(5): 326-330, 1984

Evaluation of an enzyme immunoassay for prostatic acid phosphatase utilizing monoclonal antibodies. World Journal of Urology 4(3): 153-158, 1986

Evaluation of a monoclonal antibody-based immunoradiometric assay for prostatic acid phosphatase. American Journal of Clinical Pathology 79(1): 114-119, 1983

Development and evaluation of a monoclonal antibody based assay for total triiodothyronine on the Abbott AxSYM immunoassay analyzer. Clinical Chemistry 49(S6): A44, June, 2003

Serum prostatic acid phosphatase (PAP): monoclonal enzyme-linked immunoassay compared to polyclonal radioimmunoassay. Annals of Clinical and Laboratory Science 14(1): 21-26, 1984

Generation of monoclonal antibodies to prostatic acid phosphatase isoenzyme 2 and application in solid-phase enzyme immunoassay. Biotechnology and Applied Biochemistry 11(1): 89-95, 1989

The evaluation of a new enzyme immunoassay for the measurement of prostatic acid phosphatase. Clinica Chimica Acta 113(1): 27-34, 1981

Immunohistochemical study of prostatic acid phosphatase and prostatic specific antigen in prostatic carcinoma--a comparison of monoclonal antibody to polyclonal antibody. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 78(11): 1992-1997, 1987

The evaluation of a new radio immunoassay kit for prostatic acid phosphatase 1. setting upper limit of serum prostatic acid phosphatase level. Acta Urologica Japonica 27(11): 1415-1425, 1981